Arvinas, Inc. (ARVN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARVN POWR Grades
- Value is the dimension where ARVN ranks best; there it ranks ahead of 75.57% of US stocks.
- ARVN's strongest trending metric is Growth; it's been moving down over the last 177 days.
- ARVN ranks lowest in Momentum; there it ranks in the 4th percentile.
ARVN Stock Summary
- Of note is the ratio of ARVINAS INC's sales and general administrative expense to its total operating expenses; just 8.31% of US stocks have a lower such ratio.
- For ARVN, its debt to operating expenses ratio is greater than that reported by just 5.62% of US equities we're observing.
- Revenue growth over the past 12 months for ARVINAS INC comes in at 181.37%, a number that bests 95.83% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ARVN, based on their financial statements, market capitalization, and price volatility, are FATE, DNLI, ATRA, NTLA, and XNCR.
- ARVN's SEC filings can be seen here. And to visit ARVINAS INC's official web site, go to www.arvinas.com.
ARVN Valuation Summary
- In comparison to the median Healthcare stock, ARVN's EV/EBIT ratio is 177.27% lower, now standing at -5.1.
- ARVN's price/earnings ratio has moved up 12.5 over the prior 55 months.
Below are key valuation metrics over time for ARVN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ARVN | 2023-03-24 | 10.7 | 2.5 | -5.0 | -5.1 |
| ARVN | 2023-03-23 | 10.7 | 2.5 | -5.0 | -5.1 |
| ARVN | 2023-03-22 | 11.2 | 2.6 | -5.2 | -5.3 |
| ARVN | 2023-03-21 | 11.8 | 2.7 | -5.5 | -5.6 |
| ARVN | 2023-03-20 | 12.4 | 2.9 | -5.7 | -5.9 |
| ARVN | 2023-03-17 | 12.1 | 2.8 | -5.6 | -5.8 |
ARVN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARVN has a Quality Grade of D, ranking ahead of 9.31% of graded US stocks.
- ARVN's asset turnover comes in at 0.036 -- ranking 344th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ARVN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.036 | 1 | -0.601 |
| 2021-03-31 | 0.044 | 1 | -0.743 |
| 2020-12-31 | 0.057 | 1 | -0.721 |
| 2020-09-30 | 0.088 | 1 | -0.470 |
| 2020-06-30 | 0.178 | 1 | -0.396 |
| 2020-03-31 | 0.187 | 1 | -0.389 |
ARVN Price Target
For more insight on analysts targets of ARVN, see our ARVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $130.77 | Average Broker Recommendation | 1.27 (Strong Buy) |
ARVN Stock Price Chart Interactive Chart >
ARVN Price/Volume Stats
| Current price | $26.15 | 52-week high | $75.39 |
| Prev. close | $26.60 | 52-week low | $25.35 |
| Day low | $25.93 | Volume | 347,501 |
| Day high | $26.86 | Avg. volume | 501,419 |
| 50-day MA | $31.67 | Dividend yield | N/A |
| 200-day MA | $41.01 | Market Cap | 1.39B |
Arvinas, Inc. (ARVN) Company Bio
Arvinas Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.
Latest ARVN News From Around the Web
Below are the latest news stories about ARVINAS INC that investors may wish to consider to help them evaluate ARVN as an investment opportunity.
Arvinas to Participate in Upcoming Investor ConferencesNEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: Cowen 43rd Annual Health Care Conference on Monday, March 6. Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat. A li |
A Look At The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)Key Insights Using the 2 Stage Free Cash Flow to Equity, Arvinas fair value estimate is US$40.44 With US$32.94 share... |
Arvinas Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsArvinas ( NASDAQ:ARVN ) Full Year 2022 Results Key Financial Results Revenue: US$131.4m (up 181% from FY 2021). Net... |
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue EstimatesArvinas, Inc. (ARVN) delivered earnings and revenue surprises of -50% and 8.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase 2 monotherapy expansion data from the VERITAC trial for the treatment of patients with metastatic or locally advanced ER+/HER2- breast cancer in a late-line setting – – Gained alignment with FDA on an approach to the planned 1L Phase 3 trial with ARV-471 in combination with palbociclib to enable trial initiation in 2H 2023 – NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE |
ARVN Price Returns
| 1-mo | -18.23% |
| 3-mo | -20.57% |
| 6-mo | -41.63% |
| 1-year | -59.34% |
| 3-year | -33.56% |
| 5-year | N/A |
| YTD | -23.56% |
| 2022 | -58.35% |
| 2021 | -3.29% |
| 2020 | 106.69% |
| 2019 | 219.77% |
| 2018 | N/A |
Continue Researching ARVN
Here are a few links from around the web to help you further your research on Arvinas Inc's stock as an investment opportunity:Arvinas Inc (ARVN) Stock Price | Nasdaq
Arvinas Inc (ARVN) Stock Quote, History and News - Yahoo Finance
Arvinas Inc (ARVN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...